A Three-part, Phase 1, Single-ascending, and Multiple-ascending Dose Escalation Study in Healthy Volunteers and Subjects with Systemic Amlyoidosis to Assess the Safety Tolerability, and Pharmacokinetics of AT-02 (NCT05521022)
AT02-001
This trial is No longer recruiting
Registration number NCT05521022
Program & service
This trial is being run with the Heart & Lung service, and as part of the Cardiology program.
Trial phase
Phase 1
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Associate Professor James Hare
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR